TY - JOUR
T1 - Increased risk of osteoporosis following commonly used first-line treatments for lymphoma
T2 - a Danish Nationwide Cohort Study
AU - Baech, Joachim
AU - Hansen, Steen Moeller
AU - Jakobsen, Lasse Hjort
AU - Øvlisen, Andreas K
AU - Severinsen, Marianne Tang
AU - Brown, Peter de Nully
AU - Vestergaard, Peter
AU - Frederiksen, Henrik
AU - Jørgensen, Judit
AU - Starklint, Jørn
AU - Josefsson, Pär
AU - Hammer, Troels
AU - Clausen, Michael Roost
AU - Torp-Pedersen, Christian
AU - Jensen, Paw
AU - El-Galaly, Tarec Christoffer
PY - 2020/6
Y1 - 2020/6
N2 - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.
AB - High-dose prednisolone is used in first-line treatment for lymphoma, but the potential adverse impact on bone health is unclear. Danish patients with diffuse large B-cell lymphoma or follicular lymphoma diagnosed between 2000 and 2012 were matched to the background population. Osteoporotic events (osteoporosis treatment or low-energy fracture) were identified using the Danish National Patient Registry and Prescription Registry. In total, 2589 patients and 12,945 controls were included. Lymphoma patients had increased risk of osteoporotic events compared to the matched population (hazard ratio 1.61 [95% confidence interval 1.40;1.84]). The 5- and 10-year cumulative risks of osteoporotic events for lymphoma patients were 10.0% [8.6;11.4] and 16.3% [13.8;18.7], whereas corresponding risks in the background population were 6.8% [6.3;7.3] and 13.5% [12.4;14.6]. Patients without osteoporotic event in the first two years after treatment were not at higher risk of osteoporotic events in subsequent years. Risk factors for osteoporotic events were female sex and age >70 years.
KW - Chemotherapeutic approaches
KW - immunotherapeutic approaches
KW - lymphoma and Hodgkin disease
U2 - 10.1080/10428194.2020.1723015
DO - 10.1080/10428194.2020.1723015
M3 - Article
C2 - 32043382
SN - 1042-8194
VL - 61
SP - 1345
EP - 1354
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 6
ER -